We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




PET Measures Breast Cancer Patients Response to Therapy

By MedImaging International staff writers
Posted on 16 Jun 2009
Print article
Noninvasive imaging can measure how well patients with the most common form of breast cancer, estrogen receptor-positive type, respond to standard aromatase inhibitor therapy after only two weeks and demonstrates similar findings that more invasive needle sampling identifies, according to new findings.

Utilizing positron emission tomography (PET) scanning and a glucose analogue called fluorodeoxyglucose (FDG), a research team led by Hannah Linden, M.D. and David Mankoff, M.D., from the Seattle Cancer Care Alliance and the University of Washington (Seattle, USA), scanned 21 patients before and after two weeks of aromatase inhibitor therapy. Many of the patients also underwent a needle biopsy as a control measure to compare the two techniques.

The results--16 of the 21 patients had a greater than 20% decline in FDG values-- "paralleled perfectly” with earlier research performed by UK-based researchers who used needle biopsies to measure whether the proliferation of cancer cells was slowed by therapy, according to Dr. Linden, who is a breast cancer oncologist.

"Our findings are exciting because they suggest that we can measure a patient's response to therapy noninvasively, and PET scanning provides us simultaneous quantitative metabolic measurements at multiple tumor sites,” Dr. Linden said. "PET has the potential to be a powerful tool to help doctors make important treatment decisions in as little as two weeks instead of two or more months.”

Patients with estrogen receptor-positive cancer have remained largely unevaluated in clinical trials because they are very difficult to image, according to Dr. Linden. "Our work allowed us to study a common problem in a way that's not been done before and to help more people. More work needs to be done but in my mind this was a homerun,” Dr. Linden said.

The study's findings were presented at the American Society of Clinical Oncology (ASCO) annual meeting, held May 29-June 2, 2009, Orlando, FL, USA.

Related Links:

University of Washington


Digital X-Ray Detector Panel
Acuity G4
New
Cylindrical Water Scanning System
SunSCAN 3D
New
Biopsy Software
Affirm® Contrast
Digital Radiographic System
OMNERA 300M

Print article

Channels

Radiography

view channel
Image: AI can identify “mammographically-visible” types of interval cancers earlier by flagging them at the time of screening (Photo courtesy of ScreenPoint Medical)

AI Improves Early Detection of Interval Breast Cancers

Interval breast cancers, which occur between routine screenings, are easier to treat when detected earlier. Early detection can reduce the need for aggressive treatments and improve the chances of better outcomes.... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.